Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.

Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB.

PLoS One. 2012;7(1):e29941. doi: 10.1371/journal.pone.0029941. Epub 2012 Jan 6.

2.

Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents.

Sepulveda J, Mukherjee J, Tzipori S, Simpson LL, Shoemaker CB.

Infect Immun. 2010 Feb;78(2):756-63. doi: 10.1128/IAI.01084-09. Epub 2009 Nov 16.

3.

Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein.

Mukherjee J, Dmitriev I, Debatis M, Tremblay JM, Beamer G, Kashentseva EA, Curiel DT, Shoemaker CB.

PLoS One. 2014 Aug 29;9(8):e106422. doi: 10.1371/journal.pone.0106422. eCollection 2014.

4.

Antibody protection against botulinum neurotoxin intoxication in mice.

Cheng LW, Stanker LH, Henderson TD 2nd, Lou J, Marks JD.

Infect Immun. 2009 Oct;77(10):4305-13. doi: 10.1128/IAI.00405-09. Epub 2009 Aug 3.

5.

Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.

Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, Zhou XW, Wang RL, Wang S, Yu WY, Huang PT, Sun ZW.

Clin Immunol. 2010 Nov;137(2):271-80. doi: 10.1016/j.clim.2010.07.005. Epub 2010 Aug 8.

PMID:
20696619
6.

Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.

Yu YZ, Zhang SM, Wang WB, Du Y, Zhu HQ, Wang RL, Zhou XW, Lin JB, Wang S, Yu WY, Huang PT, Sun ZW.

Biochimie. 2010 Oct;92(10):1315-20. doi: 10.1016/j.biochi.2010.06.010. Epub 2010 Jun 18.

PMID:
20600570
7.

Botulinum neurotoxins and botulism: a novel therapeutic approach.

Thanongsaksrikul J, Chaicumpa W.

Toxins (Basel). 2011 May;3(5):469-88. doi: 10.3390/toxins3050469. Epub 2011 May 13. Review.

8.

Algal chloroplast produced camelid VH H antitoxins are capable of neutralizing botulinum neurotoxin.

Barrera DJ, Rosenberg JN, Chiu JG, Chang YN, Debatis M, Ngoi SM, Chang JT, Shoemaker CB, Oyler GA, Mayfield SP.

Plant Biotechnol J. 2015 Jan;13(1):117-24. doi: 10.1111/pbi.12244. Epub 2014 Sep 17.

9.

In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).

Bakherad H, Mousavi Gargari SL, Rasooli I, Rajabibazl M, Mohammadi M, Ebrahimizadeh W, Safaee Ardakani L, Zare H.

Mol Biotechnol. 2013 Oct;55(2):159-67. doi: 10.1007/s12033-013-9669-1.

PMID:
23666874
10.

Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.

Mazuet C, Dano J, Popoff MR, Créminon C, Volland H.

PLoS One. 2010 Aug 26;5(8):e12416. doi: 10.1371/journal.pone.0012416.

11.

A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.

Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, Baldwin K, Boucher C, Peters R, Beamer G, Sheoran A, Bedenice D, Tzipori S, Shoemaker CB.

Infect Immun. 2013 Dec;81(12):4592-603. doi: 10.1128/IAI.01033-13. Epub 2013 Sep 30.

12.

Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.

Sharma R, Zhao H, Al-Saleem FH, Ubaid AS, Puligedda RD, Segan AT, Lindorfer MA, Bermudez R, Elias M, Adekar SP, Simpson LL, Taylor RP, Dessain SK.

Mol Immunol. 2014 Feb;57(2):247-54. doi: 10.1016/j.molimm.2013.09.005. Epub 2013 Nov 1.

13.

A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Barash JR, Arnon SS.

J Infect Dis. 2014 Jan 15;209(2):183-91. doi: 10.1093/infdis/jit449. Epub 2013 Oct 7.

14.

Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.

Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D, Hust M.

MAbs. 2014 Mar-Apr;6(2):446-59. doi: 10.4161/mabs.27773. Epub 2014 Jan 9.

15.

Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.

Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M.

J Protein Chem. 1996 Oct;15(7):691-700.

PMID:
8968960
16.

Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.

Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr.

J Infect Dis. 1984 Sep;150(3):407-12.

PMID:
6481185
17.

Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.

You Z, Yang H, Xin W, Kang L, Gao S, Wang J, Zhang T, Wang J.

Hum Vaccin Immunother. 2014;10(8):2321-7. doi: 10.4161/hv.29433.

18.

The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Ben David A, Diamant E, Barnea A, Rosen O, Torgeman A, Zichel R.

Clin Vaccine Immunol. 2013 Aug;20(8):1266-73. doi: 10.1128/CVI.00268-13. Epub 2013 Jun 12.

19.

Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain.

Rossotti MA, González-Techera A, Guarnaschelli J, Yim L, Camacho X, Fernández M, Cabral P, Leizagoyen C, Chabalgoity JA, González-Sapienza G.

MAbs. 2015;7(5):820-8. doi: 10.1080/19420862.2015.1068491.

20.

Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Gil LA, da Cunha CE, Moreira GM, Salvarani FM, Assis RA, Lobato FC, Mendonça M, Dellagostin OA, Conceição FR.

PLoS One. 2013 Jul 31;8(7):e69692. doi: 10.1371/journal.pone.0069692. Print 2013.

Items per page

Supplemental Content

Write to the Help Desk